Home › Companies › Y-MABS THERAPEUTICS INC. › 2023-2024
Compiled from SEC Form N-PX filings and Y-MABS THERAPEUTICS INC.’s Form 8-K, filed 2024-06-13 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2023-2024 2025-2026
Explore Y-MABS THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are Y-MABS THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-13 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Michael Rossi | 28,429,656 | -- | -- | 65,392 | 3,466,788 | Majority: yes |
| Elect Director: Thomas Gad | 21,845,733 | -- | -- | 6,649,315 | 3,466,788 | Majority: yes |
| Elect Director: Johan Wedell-Wedellsborg | 21,920,196 | -- | -- | 6,574,852 | 3,466,788 | Majority: yes |
| Proposal 2: Ratification of the Appointment of the Independent Registered Public Accounting Firm The Company's stockholders approved Proposal 2 | 31,959,182 | 2,489 | 164 | -- | -- | Majority: yes |
| Proposal 3: Advisory Vote on the Compensation of the Named Executive Officers The Company's stockholders approved Proposal 3 | 27,772,834 | 721,693 | 521 | -- | 3,466,788 | Majority: yes |
Source: Y-MABS THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-13 — read the filing on EDGAR.
Each item below shows how the 137 asset managers that disclosed a Y-MABS THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Y-MABS THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Advisory Vote on the Compensation of the Named Executive Officers The Company's stockholders approved Proposal 3”): 27,772,834 for, 721,693 against, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,882,638 outstanding shares: 63% for, 2% against (65% of the company cast a for/against vote).
The 137 asset managers below cast 95% of the shares they voted on this item FOR (17,687,669 for, 933,578 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 2,288,643 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 2,194,278 | 0 | 0 | 0 | For |
| Vanguard | 2,055,891 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 1,831,000 | 0 | 0 | 0 | For |
| BlackRock | 1,579,745 | 3,404 | 0 | 0 | For |
| Point72 | 1,221,592 | 0 | 0 | 0 | For |
| DE Shaw | 857,000 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 774,200 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 538,563 | 0 | 0 | 0 | For |
| Charles Schwab | 501,074 | 0 | 0 | 0 | For |
| Fidelity | 485,907 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 473,565 | 0 | 0 | 0 | For |
| State Street | 403,739 | 781 | 0 | 0 | For |
| Goldman Sachs | 305,821 | 0 | 0 | 0 | For |
| Caligan Partners LP | 260,702 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 220,809 | 0 | 0 | 0 | For |
| Northern Trust | 145,546 | 35 | 0 | 0 | For |
| Wellington | 0 | 132,643 | 0 | 0 | Against |
| SEI | 0 | 132,569 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 123,118 | 0 | 0 | 0 | For |
| Equitable | 120,603 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 118,681 | 0 | 0 | 0 | For |
| Cormorant Asset Management, LP | 100,251 | 0 | 0 | 0 | For |
| American Century | 0 | 93,964 | 0 | 0 | Against |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 82,188 | 0 | 0 | 0 | For |
Showing the 25 largest of 137 asset managers. See all 137 in the interactive database.
Combines 3 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Y-MABS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Johan Wedell-Wedellsborg”): 21,920,196 for, 6,574,852 withheld, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,882,638 outstanding shares: 49.9% for, 15% withheld (65% of the company cast a for/withheld vote).
The 50 asset managers below cast 100% of the shares they voted on this item FOR (4,032,646 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,004,435 | 0 | 0 | 0 | For |
| BlackRock | 950,721 | 0 | 0 | 0 | For |
| Fidelity | 457,504 | 0 | 0 | 0 | For |
| Charles Schwab | 250,537 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 184,618 | 0 | Abstain |
| Equitable | 120,603 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 82,188 | 0 | Abstain |
| BRIDGEWAY FUNDS INC | 0 | 0 | 80,759 | 0 | Abstain |
| SEI | 65,840 | 0 | 0 | 0 | For |
| Lincoln Financial | 472 | 0 | 49,179 | 0 | Abstain |
| Nationwide | 359 | 0 | 47,423 | 0 | Abstain |
| American Century | 0 | 0 | 46,982 | 0 | Abstain |
| TIAA | 40,732 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 25,685 | 0 | Abstain |
| Federated Hermes | 25,345 | 0 | 0 | 0 | For |
| Global X | 25,001 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 18,713 | 0 | 0 | 0 | For |
| ETF Series Solutions | 0 | 0 | 16,463 | 0 | Abstain |
| AQR | 0 | 0 | 15,930 | 0 | Abstain |
| CLEARWATER INVESTMENT TRUST | 15,137 | 0 | 0 | 0 | For |
| Legg Mason | 0 | 0 | 14,879 | 0 | Abstain |
| John Hancock | 0 | 0 | 14,567 | 0 | Abstain |
| HC CAPITAL TRUST | 0 | 0 | 14,136 | 0 | Abstain |
| Pacific Life | 13,223 | 0 | 0 | 0 | For |
| Voya | 12,781 | 0 | 0 | 0 | For |
Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Y-MABS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Michael Rossi”): 28,429,656 for, 65,392 withheld, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,882,638 outstanding shares: 65% for, 0.2% withheld (65% of the company cast a for/withheld vote).
The 50 asset managers below cast 100% of the shares they voted on this item FOR (4,649,819 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,004,435 | 0 | 0 | 0 | For |
| BlackRock | 950,721 | 0 | 0 | 0 | For |
| Fidelity | 457,504 | 0 | 0 | 0 | For |
| Charles Schwab | 250,537 | 0 | 0 | 0 | For |
| Goldman Sachs | 184,618 | 0 | 0 | 0 | For |
| Equitable | 120,603 | 0 | 0 | 0 | For |
| MFS | 82,188 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 80,759 | 0 | 0 | 0 | For |
| SEI | 65,840 | 0 | 0 | 0 | For |
| Lincoln Financial | 48,097 | 0 | 1,554 | 0 | For |
| Nationwide | 47,782 | 0 | 0 | 0 | For |
| American Century | 46,982 | 0 | 0 | 0 | For |
| TIAA | 40,732 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 25,685 | 0 | Abstain |
| Federated Hermes | 25,345 | 0 | 0 | 0 | For |
| Global X | 25,001 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 18,713 | 0 | 0 | 0 | For |
| ETF Series Solutions | 16,463 | 0 | 0 | 0 | For |
| AQR | 15,930 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 15,137 | 0 | 0 | 0 | For |
| Legg Mason | 14,879 | 0 | 0 | 0 | For |
| John Hancock | 14,567 | 0 | 0 | 0 | For |
| HC CAPITAL TRUST | 14,136 | 0 | 0 | 0 | For |
| Pacific Life | 13,223 | 0 | 0 | 0 | For |
| Voya | 12,781 | 0 | 0 | 0 | For |
Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.
Combines 3 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Y-MABS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Thomas Gad”): 21,845,733 for, 6,649,315 withheld, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,882,638 outstanding shares: 49.8% for, 15% withheld (65% of the company cast a for/withheld vote).
The 50 asset managers below cast 100% of the shares they voted on this item FOR (3,957,945 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,004,435 | 0 | 0 | 0 | For |
| BlackRock | 950,721 | 0 | 0 | 0 | For |
| Fidelity | 457,504 | 0 | 0 | 0 | For |
| Charles Schwab | 250,537 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 184,618 | 0 | Abstain |
| Equitable | 58,683 | 0 | 61,920 | 0 | Abstain |
| MFS | 0 | 0 | 82,188 | 0 | Abstain |
| BRIDGEWAY FUNDS INC | 0 | 0 | 80,759 | 0 | Abstain |
| SEI | 65,840 | 0 | 0 | 0 | For |
| Lincoln Financial | 472 | 0 | 49,179 | 0 | Abstain |
| Nationwide | 359 | 0 | 47,423 | 0 | Abstain |
| American Century | 0 | 0 | 46,982 | 0 | Abstain |
| TIAA | 40,732 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 25,685 | 0 | Abstain |
| Federated Hermes | 25,345 | 0 | 0 | 0 | For |
| Global X | 25,001 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 18,713 | 0 | 0 | 0 | For |
| ETF Series Solutions | 0 | 0 | 16,463 | 0 | Abstain |
| AQR | 0 | 0 | 15,930 | 0 | Abstain |
| CLEARWATER INVESTMENT TRUST | 15,137 | 0 | 0 | 0 | For |
| Legg Mason | 0 | 0 | 14,879 | 0 | Abstain |
| John Hancock | 0 | 0 | 14,567 | 0 | Abstain |
| HC CAPITAL TRUST | 0 | 0 | 14,136 | 0 | Abstain |
| Pacific Life | 13,223 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 12,781 | 0 | Abstain |
Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Y-MABS THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Ratification of the Appointment of the Independent Registered Public Accounting Firm The Company's stockholders approved Proposal 2”): 31,959,182 for, 2,489 against, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,882,638 outstanding shares: 73% for, 0.1% against (73% of the company cast a for/against vote).
The 50 asset managers below cast 100% of the shares they voted on this item FOR (4,685,464 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,004,435 | 0 | 0 | 0 | For |
| BlackRock | 950,721 | 0 | 0 | 0 | For |
| Fidelity | 457,504 | 0 | 0 | 0 | For |
| Charles Schwab | 250,537 | 0 | 0 | 0 | For |
| Goldman Sachs | 184,618 | 0 | 0 | 0 | For |
| Equitable | 120,603 | 0 | 0 | 0 | For |
| MFS | 82,188 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 80,759 | 0 | 0 | 0 | For |
| SEI | 65,840 | 0 | 0 | 0 | For |
| Lincoln Financial | 49,651 | 0 | 0 | 0 | For |
| Nationwide | 47,782 | 0 | 0 | 0 | For |
| American Century | 46,982 | 0 | 0 | 0 | For |
| TIAA | 40,732 | 0 | 0 | 0 | For |
| Dimensional | 25,685 | 0 | 0 | 0 | For |
| Federated Hermes | 25,345 | 0 | 0 | 0 | For |
| Global X | 25,001 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 18,713 | 0 | 0 | 0 | For |
| ETF Series Solutions | 16,463 | 0 | 0 | 0 | For |
| AQR | 15,930 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 15,137 | 0 | 0 | 0 | For |
| Legg Mason | 14,879 | 0 | 0 | 0 | For |
| John Hancock | 14,567 | 0 | 0 | 0 | For |
| HC CAPITAL TRUST | 14,136 | 0 | 0 | 0 | For |
| Pacific Life | 13,223 | 0 | 0 | 0 | For |
| Voya | 12,781 | 0 | 0 | 0 | For |
Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.
Ranked by the number of Y-MABS THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 43,882,638 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Paradigm Biocapital Advisors LP | 5.22% |
| 2 | Sofinnova Investments, Inc. | 5.00% |
| 3 | Vanguard | 4.68% |
| 4 | Polar Capital Holdings Plc | 4.17% |
| 5 | BlackRock | 3.61% |
| 6 | Point72 | 2.78% |
| 7 | DE Shaw | 1.95% |
| 8 | PICTET ASSET MANAGEMENT SA | 1.76% |
| 9 | Soleus Capital Management, L.P. | 1.23% |
| 10 | Charles Schwab | 1.14% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| The Vanguard Group | 5.11% | 13G |
| Point72 | 3.48% | 13F |
| D.E. Shaw | 2.43% | 13F |
| State Street | 1.71% | 13F |
| Geode Capital | 1.69% | 13F |
| Dimensional Fund Advisors | 0.95% | 13F |
| Northern Trust | 0.73% | 13F |
| Millennium Management | 0.64% | 13F |
| Nuveen | 0.61% | 13F |
| Charles Schwab | 0.57% | 13F |
Percentages above are of 43,882,638 shares outstanding, as reported by Y-MABS THERAPEUTICS INC. on its Form 10-Q dated 2024-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Y-MABS THERAPEUTICS INC.’s 10-Q dated 2024-04-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Y-MABS THERAPEUTICS INC.'s shareholder meeting held 2024-06-11, in the 2023-2024 proxy season, 137 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 899 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY VOTE BASIS, THE COMPENSATION OF THE COMPANY'S NAMED… — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Y-MABS THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-13.
Y-MABS THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2025-2026.